Abstract
9084 Background: 5-fluorouracil (5-FU) is widely used to treat solid tumors and is often administered via infusion pump at or near its maximum tolerated dose. The common use of infusion pumps loaded with 5-FU for infusion over several days increases the possibility of potentially lethal overdoses due to pump malfunction or misprogramming. Uridine triacetate (vistonuridine) is an orally bioavailable prodrug of uridine, a direct biochemical antagonist of 5-FU toxicity. Uridine nucleotides derived from uridine triacetate dilute intracellular fluorouridine nucleotide anabolites of 5-FU, reducing their lethal incorporation into RNA. Successful outcomes for 17 5-FU overdose patients treated with uridine triacetate were reported at ASCO in 2009, along with 13 historical cases of comparable 5-FU overdoses treated with supportive care only. Consequent increased awareness of uridine triacetate as an antidote has resulted in a significant increase in the frequency of requests for emergency use of uridine triacetate....
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
